ReviewInternational journal of nanomedicine2025
Recent Advances in Biomimetic Drug Delivery for Rheumatoid Arthritis Treatment.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Therapeutic Efficacy of Dual-Targeting Nanoparticles with Low Immunogenicity in the Treatment of Rheumatoid Arthritis.Journal of functional biomaterials · 2026Article
- Nanoparticle embedded dot matrix transdermal patches: a novel approach for targeted and controlled drug delivery in rheumatoid arthritis.Inflammopharmacology · 2026Review
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
- Research Progress on Self-Assembling Delivery Systems in Rheumatoid Arthritis.International journal of nanomedicine · 2026Review
- Screening of potential oxidative stress-related biomarkers and therapeutic drugs in rheumatoid arthritis based on integrative bioinformatics, machine learning, and molecular dynamics simulations.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) affects approximately 1% of the global population, causing debilitating joint pain and often leading to severe disability. Although conventional treatments can control the initial symptoms of RA, there is no curative treatment strategy for RA. Biomimetic nanomedicine has emerged as a promising therapeutic approach, leveraging the integration of nanoparticles with natural biomaterials to achieve targeted drug delivery and improved treatment outcomes. Beyond exogenous nano-delivery systems, the natural biomimetic strategy might offer superior biocompatibility and lower immunogenicity. This review summarizes the latest advancements in biomimetic drug delivery systems for RA and highlights the underlying mechanisms for these biomimetic carriers. We also discuss the critical factors influencing the transition of these biomimetic nanomedicines from laboratory research to clinical implementation. By emphasizing the transformative potential of biomimetic strategies in RA treatment, this review aims to provide new insights and directions for future research and clinical applications in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.